Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 5500 shares trading hands. The stock had previously closed at C$0.03.
Quest PharmaTech Price Performance
The company has a debt-to-equity ratio of 4.35, a quick ratio of 0.52 and a current ratio of 0.40. The firm has a market capitalization of C$3.38 million, a P/E ratio of 0.67 and a beta of -0.07. The company has a 50-day moving average price of C$0.03 and a 200-day moving average price of C$0.03.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
See Also
- Five stocks we like better than Quest PharmaTech
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
